Pivotal trial of monoclonal antibody TNT-1 in patients with glioblastoma.

Trial Profile

Pivotal trial of monoclonal antibody TNT-1 in patients with glioblastoma.

Not yet recruiting
Phase of Trial: Phase III

Latest Information Update: 05 Dec 2012

At a glance

  • Drugs Iodine I 131 derlotuximab biotin (Primary)
  • Indications Glioblastoma
  • Focus Registrational; Therapeutic Use
  • Most Recent Events

    • 05 Dec 2012 Status changed from planning to not yet recruiting. The trial design has been approved by the US FDA.
    • 19 Dec 2011 New trial record
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top